Using current techniques, Alzheimer’s disease, the most frequent cause of dementia, can only be detected once the typical plaques have formed in the brain. At this point, therapy seems no longer possible. However, the first changes caused by Alzheimer’s take place on the protein level up to 20 years sooner. A two-tier method developed at Ruhr-Universität Bochum (RUB) can help detect the disease at a much earlier stage. The researchers from Bochum published their report in the March 2019 edition of the journal “Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring”.
“This has paved the way for early-stage therapy approaches, where the as yet inefficient drugs on which we had pinned our hopes may prove effective,” says Professor Klaus Gerwert from the Department of Biophysics at RUB.
Protein folds incorrectly
In Alzheimer’s patients, the amyloid beta protein folds incorrectly due to pathological changes long before the first symptoms occur. A team of researchers headed by Klaus Gerwert successfully diagnosed this misfolding using a simple blood test; as a result, the disease can be detected approximately eight years before the first clinical symptoms occur. The test wasn’t suitable for clinical applications however: it did detect 71 per cent of Alzheimer’s cases in symptomless stages, but at the same time provided false positive diagnoses for nine per cent of the study participants. In order to increase the number of correctly identified Alzheimer’s cases and to reduce the number of false positive diagnoses, the researchers poured a lot of time and effort into optimising the test.
As a result, they have now introduced the two-tier diagnostic method. To this end, they use the original blood test to identify high-risk individuals. Subsequently, they add a dementia-specific biomarker, namely tau protein, to run further tests with those test participants whose Alzheimer’s diagnosis was positive in the first step. If both biomarkers show a positive result, there is a high likelihood of Alzheimer’s disease. “Through the combination of both analyses, 87 of 100 Alzheimer’s patients were correctly identified in our study,” summarises Klaus Gerwert. “And we reduced the number of false positive diagnoses in healthy subjects to 3 of 100. The second analysis is carried out in cerebrospinal fluid that is extracted from the spinal cord.
“Now, new clinical studies with test participants in very early stages of the disease can be launched,” points out Gerwert. He is hoping that the existing therapeutic antibodies will still have an effect. “Recently, two major promising studies have failed, especially Crenezumab and Aducanumab – not least because it had probably already been too late by the time therapy was taken up. The new test opens up a new therapy window.”
“Once amyloid plaques have formed, it seems that the disease can no longer be treated,” says Dr. Andreas Nabers, head of the research group and co-developer of the Alzheimer’s sensor. “If our attempts to arrest the progression of Alzheimer’s fail, it will put a lot of strain on our society.”
Sensor test is simple and robust
The blood test has been upgraded to a fully automated process at the RUB Department of Biophysics. “The sensor is easy to use, robust when it comes to fluctuation in concentration of biomarkers, and standardised,” explains Andreas Nabers. “We are now conducting in-depth research to detect the second biomarker, namely tau protein, in the blood, in order to supply a solely blood-based test in future,” concludes Klaus Gerwert.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Local Alzheimer’s Association chapter comments on new Ohio legislationon November 18, 2019 at 11:56 pm
AVON, Ohio -- Ohio Gov. Mike DeWine recently signed legislation into law to “help the state confront the sweeping economic and social impact of Alzheimer’s disease and related dementias,” according to ...
- Alzheimer's Trial: Lessons From a Failed Drugon November 18, 2019 at 8:30 pm
Minocycline (Minocin), an anti-inflammatory tetracycline that crosses the blood-brain barrier and inhibits proinflammatory microglia, did not improve cognitive or functional performance in people with ...
- Alzheimer's Association shines light on caregiverson November 18, 2019 at 6:49 pm
THIS BREAKING NEWS. LIVING WITH ALZHEIMER’S IS A LIFE ALTERING EXPERIENCE FOR PATIENTS AND THEIR FAMILIES. THIS MONTH, WE CELEBRATE AND APPRECIATE THOSE WHO HELP PEOPLE WITH ALZHEIMER’S AND THOSE WHO ...
- Fight for a cure: WXII 12's Lanie Pope says mother's Alzheimer's diagnosis changed course of her lifeon November 18, 2019 at 6:19 pm
As Alzheimer's impacts millions of families every year, WXII 12 Chief Meteorologist Lanie Pope said her mother's diagnosis with the disease didn't just take her mom's life, but also changed the course ...
- Avanir Pharmaceuticals and Alzheimer's Orange County Partner for 2019 Walk4ALZ and Run4ALZ to Fight Alzheimer's and Dementiaon November 18, 2019 at 4:17 pm
ALISO VIEJO, Calif., Nov. 18, 2019 /PRNewswire/ -- On a beautiful Orange County morning, Avanir Pharmaceuticals, Inc. joined the nonprofit Alzheimer's Orange County to raise awareness and funds to ...
- Edward Jones Surpasses $20 Million in Fight Against Alzheimer'son November 18, 2019 at 4:07 pm
Goal reached one year early thanks to generosity of associates, clients and communities ST. LOUIS, Nov. 18, 2019 /PRNewswire/ -- Financial-services firm Edward Jones announced today that during the ...
- Alzheimer’s Association, Ad Council create podcast to promote early detectionon November 18, 2019 at 10:40 am
The campaign features interviews with five notable Alzheimer’s activists. Alzheimer’s is a difficult burden to bear for both patients and their families, which is why the Alzheimer’s Association and ...
- Genetic Variant Could Boost Precision Medicine for Alzheimer’son November 18, 2019 at 6:59 am
November 18, 2019 - Researchers at Massachusetts General Hospital (MGH) have discovered that certain genetic variants may help protect against Alzheimer’s disease. Their findings could hold important ...
- Alzheimer's can be hard to discuss. This ad campaign hopes to simplify that.on November 18, 2019 at 6:01 am
Looking to better understand Alzheimer's and its deep, emotional impact? A new ad campaign, structured as a podcast miniseries and made in collaboration between the Alzheimer's Association, the Ad ...
- Q&A: Brightview Senior Living director talks initiatives, fundraising, education during Alzheimer’s Awareness monthon November 17, 2019 at 12:10 pm
November has been recognized as Alzheimer’s Awareness month in the United States since 1983 in honor of the millions of people who have the neurological disease and the millions who care for a loved ...
via Bing News